DAFNA Capital Management’s Aquestive Therapeutics AQST Stock Holding History

DAFNA Capital Management’s Portfolio AQST Stock Details AQST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.53M	Sell	368,415 -7,500	-2%	-$30.4K	0.35%	51
2025 Q4	$2.43M	Sell	375,915 -136,674	-27%	-$852K	0.56%	44
2025 Q3	$2.87M	Buy	512,589 +370,589	+261%	+$1.6M	0.71%	37
2025 Q2	$470K	Hold	142,000	–	–	0.13%	66
2025 Q1	$412K	Buy	142,000 +15,000	+12%	+$45.4K	0.12%	74
2024 Q4	$452K	Sell	127,000 -462,561	-78%	-$2.13M	0.11%	73
2024 Q3	$2.94M	Buy	589,561 +59,561	+11%	+$232K	0.69%	37
2024 Q2	$1.38M	Buy	530,000 +30,000	+6%	+$100K	0.33%	53
2024 Q1	$2.13M	Buy	+500,000	New	+$1.66M	0.48%	42

Other funds holding AQST

BCM

Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

DAFNA Capital Management's AQST Position: Q1 2026 in Review

DAFNA Capital Management reduced its Aquestive Therapeutics (AQST) stake by 2% in Q1 2026, selling an estimated $30.4K and leaving 368,415 shares worth $1.53M. The position accounts for 0.35% of the portfolio, ranked #51.

DAFNA Capital Management first reported a position in AQST in Q1 2024 and has held it in 9 quarters since. The position peaked at $2.94M in Q3 2024. 179 funds tracked by Wall St. Rank hold AQST as of Q1 2026.

DAFNA Capital Management held 368,415 shares of Aquestive Therapeutics worth $1.53M as of Q1 2026.
DAFNA Capital Management sold 7,500 Aquestive Therapeutics shares in Q1 2026, an estimated $30.4K.
Aquestive Therapeutics made up 0.35% of DAFNA Capital Management's portfolio in Q1 2026, its #51 holding.
DAFNA Capital Management first reported a position in Aquestive Therapeutics in Q1 2024 and has held it in 9 quarters since.
DAFNA Capital Management's Aquestive Therapeutics position peaked at $2.94M in Q3 2024.
179 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2026.

Based on DAFNA Capital Management's 13F filing for Q1 2026, filed 15 May 2026.